Neuren Pharmaceuticals (ASX:NEU) started the development of NNZ-2591 for the potential treatment of hypoxic-ischemic encephalopathy (HIE), according to a Thursday filing with the Australian bourse.
HIE is a type of brain injury resulting from inadequate oxygen or blood flow in a baby's brain before or shortly after birth, the filing said.
The company aims for a pre-investigational new drug meeting with the US Food and Drug Administration in the fourth quarter of the year before initiating a clinical trial in patients with HIE, per the filing.
Shares were up 3% in morning trade Thursday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。